RESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Paeoniae Radix Rubra (PRR) is the dried root of Paeonia lactiflora Pall, which has been widely used to anti-thrombotic, lipid-lowering, anti-spasmodic, antioxidant, antibacterial, hepatoprotective, and anti-tumor in Chinese clinical practice. Recent research has demonstrated that PRR plays a significant anti-tumor role in animal models of tumor-bearing. AIM OF THE STUDY: There has not been the evaluation of the anti-tumor effects of PRR. This study conducts a meta-analysis to assess the anti-tumor efficacy of PRR on animal models, providing scientific evidence for clinical application of PRR in the adjuvant therapy of tumors. MATERIALS AND METHODS: English databases (PubMed, The Cochrane Library, Embase, and Web of Science) and Chinese databases (CNKI, WanFang, SinoMed, CTSJ-VIP) were used to search all pertinent animal studies investigating the anti-tumor effects of PRR and its extracts. The quality of the included studies was evaluated using the SYRCLE animal experiment risk assessment tool, and statistical analysis was carried out using Revman 5.3 software. Egger's test and funnel plots were used to assess potential publication bias in the studies. RESULTS: The initial search produced a total of 3905 potentially pertinent studies, and 24 studies met the inclusion criteria. These studies included animal tumor models of hepatocellular carcinoma, lung cancer, sarcoma, bladder cancer, leukemia, colon cancer, glioblastoma, and pancreatic cancer. The meta-analysis findings demonstrated that both PRR and its extracts significantly inhibited tumor growth in animals. Compared with the control group, PRR substantively inhibited tumor volume (SMD, -3.09; 95% CI, [-4.05, -2.13]; P < 0.0001), reduced tumor weight (SMD, -1.08; 95% CI, [-1.37, -0.78]; P < 0.0001), decreased tumor number (SMD, -2.16; 95% CI, [-3.45, -0.86]; P = 0.001), and prolonged the survival duration time (SMD, 0.97; 95% CI, [0.23, 1.71]; P = 0.01) on the experimental animals. CONCLUSIONS: PRR displayed a potential therapeutic efficacy on eight tumors in animal models including hepatocellular carcinoma, lung cancer, sarcoma, bladder cancer, leukemia, colon cancer, glioblastoma, and pancreatic cancer. However, the quality and quantity of included studies may affect the accuracy of positive results. In the future, more high-quality randomized controlled animal experiments are need for meta-analysis.
Asunto(s)
Antineoplásicos Fitogénicos , Neoplasias , Paeonia , Animales , Paeonia/química , Antineoplásicos Fitogénicos/farmacología , Antineoplásicos Fitogénicos/uso terapéutico , Neoplasias/tratamiento farmacológico , Neoplasias/patología , Modelos Animales de Enfermedad , Humanos , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Raíces de PlantasRESUMEN
CONTEXT: Traditional Chinese medicine plays an important role in the prevention and treatment of heart failure (HF). Linggui Zhugan decoction has been approved for clinical treatment of chronic HF. However, the mechanism is still unclear. OBJECTIVE: The effect of Linggui Zhugan decoction on the Wnt/ß-catenin signaling pathway in rat myocardium was studied to investigate the mechanism by Linggui Zhugan decoction effects ventricular remodeling in rats with heart failure after myocardial infarction. METHOD: A rat model of HF after myocardial infarction was prepared by ligating the left anterior descending coronary artery. After 6 weeks of intervention with Linggui Zhugan decoction, the effect of Linggui Zhugan decoction on the cardiac function of chronic HF model rats was observed. Myocardial infarct size was measured by triphenyl tetrazolium chloride (TTC) staining. Enzyme linked immunosorbent assays (ELISAs) were used to measure NT-proBNP and sST-2 concentrations in rat serum. Hematoxylin and eosin (H&E) staining, and Masson's trichrome staining were used to observe the morphology of myocardial tissue; immunohistochemistry was used to detect the protein expression of type I collagen and type III collagen in myocardial tissue; and mRNA expression levels of Wnt3a, GSK-3ß, ß-catenin, and c-Myc in the infarct marginal zone were detected using PCR. Protein expression of Wnt3a, p-GSK-3ß, GSK-3ß, and ß-catenin in the infarct marginal zone was detected using western blot. RESULTS: Compared with the control, Linggui Zhugan decoction reduced the levels of serum ST-2 and NT-proBNP, improved cardiac function, and reduced the deposition of collagen fiber. In addition, Linggui Zhugan decoction inhibited the expression of Wnt3a, p-GSK-3ß, and ß-catenin in cardiomyocytes. CONCLUSION: Linggui Zhugan decoction inhibits the expression of several key proteins in the Wnt/ß-catenin signaling pathway, delays cardiomyocyte hypertrophy and fibrosis, and improves cardiac function.
Asunto(s)
Insuficiencia Cardíaca , Infarto del Miocardio , Ratas , Animales , Vía de Señalización Wnt , beta Catenina/metabolismo , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Remodelación Ventricular , Insuficiencia Cardíaca/metabolismo , Infarto del Miocardio/tratamiento farmacológicoRESUMEN
Today, the University of Tartu (earlier Dorpat) belongs among the 250 best universities of the world. Its international team of pharmacologists uses powerful confocal microscopes to study apoptosis and cell death within an international consortium. Science is working on solutions to fight Alzheimer disease, which is a torture for humankind. For this to happen today, the foundation was laid by scientists of previous centuries who deserve our great respect, all of them together and everyone separately. Johannes Piiper, a well-known professor of physiology, once told me in a conversation that articles should be published in every 10 years about the men who have served as examples for the science of the present-day world and about the conditions in which their research was done. It is essential that researchers working in modern laboratories would not forget in their smugness that the laboratory has not always been a warm and well-lit room full of expensive technology, and not always have millions been allocated for research grants. Electricity came to Dorpat as late as in 1892. In the harsh Estonian winter, ice sometimes covered the inner walls of the Old Anatomical Theatre. Dorpat received railway connection in 1876. When I have made presentations in American countries, I have repeatedly been asked why the pharmacologists of the University of Tartu have not published an illustrated biography of Rudolf Richard Buchheim. As I have worked in the rooms the construction of which was directed by R. Buchheim as Dean of the Faculty of Medicine, I am trying to correct this shortcoming at least to some extent. I have written about Buchheim earlier, but then the print volume was limited. In this article, I have attempted to fill the gaps where the earlier materials have been erroneous or incomplete. So, the article will explain the formation of the large family of Buchheims. Several articles have given the impression that when Buchheim arrived in Dorpat, there were no facilities at all, and, therefore, he founded the laboratory in the basement of his dwelling house. This article will also bring clarity to that. Through O. Schmiedeberg's memories, we will see the great difficulties with which Buchheim's viewpoints broke through and were accepted. The question where Buchheim's laboratory was situated after Buchheim moved house in 1852 until the completion of the annex to the Old Anatomical Theatre in 1860 will also be answered. The article also brings some clarity about R. Buchheim's children. For the first time, it has been summed up how R. Buchheim is commemorated in different towns and countries. The article includes photos from Estonian and foreign archives; some photos have also been received from cooperation partners. Photos available on the Internet as freeware have also been used. The mid-nineteenth century brought a whole constellation of talented scientists to the German-language University of Dorpat (now Tartu in Estonia, founded 1632) on the outskirts of the Russian Empire. They did not tinker on their own but were engaged in successful cooperation. Thus, the celebrities who happened to work in Tartu simultaneously included Professor of Anatomy and Physiology Georg Friedrich Karl Heinrich Bidder; founder of physiological chemistry, chemist Carl Ernst Heinrich Schmidt; and Rudolf Richard Buchheim whom Professors E. A. Carus and F. Bidder had invited to Tartu to work as Head of the Department of Materia Medica, Dietetics and History of Medicine. Together, the three talented and hardworking scientists cleared the path to research-based medicine and wrote their names into the history of world medicine forever. By introducing chemical analysis and animal experiments, R. Buchheim laid the foundation to scientific pharmacology.
RESUMEN
The purpose of this study is to investigate whether chrysin reduces cerebral ischemia-reperfusion injury(CIRI) by inhi-biting ferroptosis in rats. Male SD rats were randomly divided into a sham group, a model group, high-, medium-, and low-dose chrysin groups(200, 100, and 50 mg·kg~(-1)), and a positive drug group(Ginaton, 21.6 mg·kg~(-1)). The CIRI model was induced in rats by transient middle cerebral artery occlusion(tMCAO). The indexes were evaluated and the samples were taken 24 h after the operation. The neurological deficit score was used to detect neurological function. The 2,3,5-triphenyl tetrazolium chloride(TTC) staining was used to detect the cerebral infarction area. Hematoxylin-eosin(HE) staining and Nissl staining were used to observe the morphological structure of brain tissues. Prussian blue staining was used to observe the iron accumulation in the brain. Total iron, lipid pero-xide, and malondialdehyde in serum and brain tissues were detected by biochemical reagents. Real-time quantitative polymerase chain reaction(RT-qPCR), immunohistochemistry, and Western blot were used to detect mRNA and protein expression of solute carrier fa-mily 7 member 11(SLC7A11), transferrin receptor 1(TFR1), glutathione peroxidase 4(GPX4), acyl-CoA synthetase long chain family member 4(ACSL4), and prostaglandin-endoperoxide synthase 2(PTGS2) in brain tissues. Compared with the model group, the groups with drug intervention showed restored neurological function, decreased cerebral infarction rate, and alleviated pathological changes. The low-dose chrysin group was selected as the optimal dosing group. Compared with the model group, the chrysin groups showed reduced content of total iron, lipid peroxide, and malondialdehyde in brain tissues and serum, increased mRNA and protein expression levels of SLC7A11 and GPX4, and decreased mRNA and protein expression levels of TFR1, PTGS2, and ACSL4. Chrysin may regulate iron metabolism via regulating the related targets of ferroptosis and inhibit neuronal ferroptosis induced by CIRI.
Asunto(s)
Isquemia Encefálica , Ferroptosis , Daño por Reperfusión , Ratas , Masculino , Animales , Ratas Sprague-Dawley , Transducción de Señal , Isquemia Encefálica/tratamiento farmacológico , Isquemia Encefálica/genética , Isquemia Encefálica/metabolismo , Ciclooxigenasa 2/metabolismo , ARN Mensajero , Infarto Cerebral , Daño por Reperfusión/tratamiento farmacológico , Daño por Reperfusión/genética , Daño por Reperfusión/metabolismo , Malondialdehído , Infarto de la Arteria Cerebral MediaRESUMEN
Objective: To investigate the effects of Linggui Zhugan Decoction on mitochondrial and oxidative damage in rats with chronic heart failure after myocardial infarction and the related mechanisms. Methods: Chronic heart failure after myocardial infarction was established by coronary artery ligation. Heart failure rats were randomly divided into three groups: Model group (n = 11), Linggui Zhugan Decoction group (n = 12), and captopril group (n = 11). Rats whose coronary arteries were only threaded and not ligated were sham group (n = 11). Cardiac function, superoxide dismutase (SOD), malondialdehyde (MDA) contents, soluble growth-stimulating expression factor (ST2), and N-terminal B-type brain natriuretic peptide precursor (NTproBNP) levels were analyzed after treatment. Moreover, the level of mitochondrial membrane potential was detected by JC-1 staining, the ultrastructural of myocardial mitochondria were observed by transmission electron microscopy. The related signal pathway of silent information regulator factor 2-related enzyme 1 (SIRT1), adenylate activated protein kinase (AMPK), phosphorylated adenylate activated protein kinase (p-AMPK), and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is an important pathway to regulate mitochondrial energy metabolism, and to initiate mitochondrial biogenesis. The expression level was detected by Western blot and reverse transcription to explore the mechanism of the decoction. Results: Compared with the model rats, Linggui Zhugan Decoction significantly improved cardiac function (p < 0.05), reduced MDA production (p < 0.01), increased SOD activity (p < 0.05), reduced ST-2(p < 0.01), and NT-proBNP(p < 0.05) levels, increased mitochondrial membrane potential, and improved mitochondria function. In addition, Linggui Zhugan Decoction upregulated the expression of SIRT1, p-AMPK, PGC-1α protein, and mRNA in cardiac myocytes. Conclusion: Linggui Zhugan Decoction can improve the cardiac function of heart failure rats by enhancing myocardial antioxidant capacity and protecting the mitochondrial function, the mechanism is related to activating SIRT1/AMPK/PGC-1α signaling pathway.
RESUMEN
ObjectiveTo explore the mechanism of Tangbikang granules (TBK) against diabetic peripheral neuropathy (DPN) based on network pharmacology and in-vivo experiment. MethodThe active components in medicinals of TBK and their target genes were searched from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The active components of the medicinals which are not included in TCMSP were searched from previous research. After the analysis of drug-likeness by SwissADME, the target genes of them were predicted with SwissTargetPrediction. DPN-related target genes were retrieved from GeneCards. The common targets of the disease and the prescription were the hub genes of TBK against DPN, which were uploaded to Metascape for Gene Ontology (GO) term enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. High-sugar and high-fat diet and low-dose streptozotocin (STZ, ip) were employed to induce diabetes in rats, and then the model rats were respectively treated with low-dose (0.625 g·kg-1), medium-dose (1.25 g·kg-1), and high-dose (2.5 g·kg-1) TBK for 12 weeks. Sensory nerve conduction velocity (SNCV) was evaluated. After hematoxylin and eosin (HE) staining, the sciatic nerve was observed under light microscope to examine the nerve damage. Real-time PCR was performed to detect the gene expression of adenosine monophosphate-activated protein kinase (AMPK) pathway-related targets in rat sciatic nerve, and Western blot to measure the protein expression of AMPK and phosphorylated (p)-AMPK in rat sciatic nerve. ResultThe main active components of TBK, such as quercetin, kaempferol, β-sitosterol, leech pteridine A, stigmasterol, and baicalein were screened out, mainly acting on interleukin-6 (IL-6), tumor necrosis factor (TNF), protein kinase B (Akt), JUN, and HSP90AA1 and signaling pathways such as AMPK, nuclear factor-κB (NF-κB), and Janus kinase/signal transducer and activator of transcription (JAK/STAT). Molecular docking results showed that β-sitosterol and stigmasterol had high binding affinity with IL-6, TNF, JUN, and HSP90AA1. As for the animal experiment, compared with the normal group, model group had low SNCV of sciatic nerve (P<0.01), disordered and loose myelinated nerve fibers with axonotmesis and demyelinization, low mRNA expression of AMPKα, AMPKβ, peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), Sirtuin 3 (SirT3), mitochondrial transcription factor A (TFAM), and low p-AMPK/AMPK ratio in sciatic nerve (P<0.05, P<0.01). Compared with the model group, TBK of the three doses raised the SNCV (P<0.01), restored nerve morphology and nerve compactness, and increased the mRNA expression of AMPKα, AMPKβ, PGC-1α, SirT3, and TFAM (P<0.05, P<0.01). The ratio of p-AMPK/AMPK in the high-dose and medium-dose TBK groups was higher than that in the model group (P<0.01), while the protein expression in the low-dose TBK group was insignificantly different from that in the model group. ConclusionTBK exerts therapeutic effect on DPN through multiple pathways and targets. The mechanism is that it activates and regulates AMPK/PGC-1α/SirT3 signaling, which lays a basis for further study of TBK in the treatment of DPN.
RESUMEN
CONTEXT: Cnidium monnieri Cusson (Apiaceae) has been used in traditional Asian medicine for thousands of years. Recent studies showed its active compound, osthole, had a good effect on osteoporosis. But there was no comprehensive analysis. OBJECTIVE: This meta-analysis evaluates the effects of osthole on osteoporotic rats and provides a basis for future clinical studies. METHODS: Chinese and English language databases (e.g., PubMed, Web of Science, Cochrane Library, Google Scholar, Embase, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, Weipu Chinese Sci-tech periodical full-text database, and Chinese BioMedical Literature Database) were searched from their establishment to February 2021. The effects of osthole on bone mineral density, osteoclast proliferation, and bone metabolism markers were compared with the effects of control treatments. RESULTS: To our knowledge, this is the first meta-analysis to evaluate osthole for the treatment of osteoporosis in rats. We included 13 randomized controlled studies conducted on osteoporotic rats. Osthole increased bone mineral density (standardized mean difference [SMD] = 3.08, 95% confidence interval [CI] = 2.08-4.09), the subgroup analysis showed that BMD significantly increased among rats in osthole <10 mg/kg/day and duration of osthole treatment >2 months. Osthole improved histomorphometric parameters and biomechanical parameters, also inhibited osteoclast proliferation and bone metabolism. CONCLUSIONS: Osthole is an effective treatment for osteoporosis. It can promote bone formation and inhibit bone absorption.
Asunto(s)
Cnidium , Osteoporosis , Animales , Densidad Ósea , Cnidium/química , Cumarinas/farmacología , Cumarinas/uso terapéutico , Osteoporosis/tratamiento farmacológico , RatasRESUMEN
OBJECTIVE: In recent years, there are several systematic reviews published on animal experiments of Traditional Chinese medicine (TCM). PRISMA (preferred reporting items for systematic reviews and meta-analysis) guidelines provide a guarantee for significantly improving the reporting quality of systematic reviews (SRs) and meta-analysis (MAs) to a certain extent; however, there are still certain defects found in the quality of SRs/MAs of animal experiments of TCM. It has been found that especially, the descriptions of the rationale and animal characteristics of TCM interventions are inadequate. As a result, we have developed a novel reporting guideline for SRs/MAs of animal experimental in the field of TCM (PRISMA-ATCM) to overcome these problems. METHODS: PRISMA-ATCM reporting guidelines were formed by analyzing both the status and quality of published SRs/MAs of animal experiments and consulting experts in the related fields, and then by Delphi consultation, consensus meeting and revision. RESULTS: Among the 27 items on the PRISMA checklist, Title (1), Structured summary (2), Rationale (3), Objectives (4), Protocol and registration (5), Eligibility criteria (6), Data items (11), Planned methods of analysis (14), Study characteristics (18), Summary of evidence (24), Limitations (25), and Funding (27) have been extensively revised and expanded, to specifically include the details about TCM intervention and animal characteristics. In addition, illustrative examples and explanations have been provided for each item. CONCLUSION: PRISMA-ATCM could markedly improve the quality SRs/MAs of animal experiments in the field of TCM.
Asunto(s)
Experimentación Animal , Medicina Tradicional China , Animales , PublicacionesRESUMEN
The diverse experiences regarding the failure of tested drugs in the fight against COVID-19 made it clear that one should at least question the requirement to apply classical preclinical development strategies that demand cell and animal efficacy models to be tested before going into clinical trials. Most animals are not susceptible to infection with SARS-CoV-2, and so this led to one-sided virus replication experiments in cells and the use of animal models that have little in common with the complex pathogenesis of COVID-19 in humans. Therefore, non-clinical development strategies were designed to meet regulatory requirements, but they did not truly reflect the situation in the clinic. This has led the search for effective agents astray in many cases. As proof of this statement, we now bring together the results of such required preclinical experiments and compare with the results in clinical trials. Two clear conclusions that can be drawn from the experience to date: The required preclinical models are unsuitable for the development of innovative treatments medical devices in the case of COVID-19 and mono-action strategies (e.g. direct antivirals) are of very little or no benefit to patients under randomized,blinded conditions. Our hypothesis is that the complex situation of COVID-19 may benefit from multi-mode drugs. Here, the molecular class of aptamers could be a solution.
Asunto(s)
Antivirales/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Descubrimiento de Drogas , Evaluación Preclínica de Medicamentos , SARS-CoV-2/efectos de los fármacos , Animales , Antivirales/farmacología , Modelos Animales de Enfermedad , Descubrimiento de Drogas/métodos , Evaluación Preclínica de Medicamentos/métodos , HumanosRESUMEN
ObjectiveTo predict the potential molecular mechanism of Erxian decoction in the treatment of anxiety disorder based on network pharmacology, and to verify the efficacy and mechanism using the animal model of maternal separation combined with restraint stress. MethodActive components and related targets of Erxian decoction were obtained by traditional Chinese medicine system pharmacology database and analysis platform (TCMSP) and SwissTargetPrediction. The targets related to anxiety disorder were screened out through GeneCards, therapeutic target database (TTD), online mendelian inheritance in man database (OMIM), and DrugBank, and the drug-disease intersection targets were obtained by taking intersections with the drug targets. The protein-protein interaction (PPI) network was constructed by the STRING database, and the core targets were screened out based on topological parameter analysis. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were carried out for the intersection targets through the Metascape platform. Maternal separation combined with restraint stress was used to induce the mouse model of anxiety disorder. From the end of lactation on the 21st postnatal day (PD21) to the completion of restraint stress on the 97th postnatal day (PD97), the mice were fed with Erxian decoction mixed with diet. The anxiety state of mice was evaluated by open field test and elevated O-maze test. The content of plasma corticosterone (CORT) in mice was detected by enzyme-linked immunosorbent assay (ELISA). The expression levels of protein kinase B (Akt1), mammalian target of rapamycin (mTOR), brain-derived neurotrophic factor (BDNF), postsynaptic density-95 (PSD95), and synaptophysin in the hippocampus of mice were detected by Western blot and real-time quantitative polymerase chain reaction (Real-time PCR). ResultNinty-seven active components and 227 action targets of Erxian decoction were obtained. There were 3 863 targets related to anxiety disorder, with 161 drug-disease intersection targets. Among these intersection targets, core targets such as Akt1, interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor (TNF), and mTOR were presumedly closely related to anxiety disorder. The results of KEGG pathway analysis showed that Erxian decoction mainly treated anxiety disorder through phosphatidylinositol 3-kinase (PI3K)/Akt, mitogen-activated protein kinase (MAPK), and neuroactive ligand-receptor interaction signaling pathways. The results of animal experiments showed that compared with the model group, the Erxian decoction group significantly increased the time of mice spent in the central zone and central crossing times and time spent in the opened arm and opened arm crossing times, with significantly increased expression levels of p-Akt1, p-mTOR, BDNF, PSD95, and synaptophysin (Syp). ConclusionErxian decoction has the multi-target and multi-pathway characteristics in the treatment of anxiety disorder, and its mechanism may be related to the improvement of synaptic plasticity and neuroinflammation by affecting Akt1, IL-1β, IL-6, TNF, mTOR, and other core targets and modulating PI3K/Akt, MAPK, as well as neuroactive ligand-receptor interaction signal pathways.
RESUMEN
ObjectiveTo predict the potential molecular mechanism of Erxian decoction in the treatment of anxiety disorder based on network pharmacology, and to verify the efficacy and mechanism using the animal model of maternal separation combined with restraint stress. MethodActive components and related targets of Erxian decoction were obtained by traditional Chinese medicine system pharmacology database and analysis platform (TCMSP) and SwissTargetPrediction. The targets related to anxiety disorder were screened out through GeneCards, therapeutic target database (TTD), online mendelian inheritance in man database (OMIM), and DrugBank, and the drug-disease intersection targets were obtained by taking intersections with the drug targets. The protein-protein interaction (PPI) network was constructed by the STRING database, and the core targets were screened out based on topological parameter analysis. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were carried out for the intersection targets through the Metascape platform. Maternal separation combined with restraint stress was used to induce the mouse model of anxiety disorder. From the end of lactation on the 21st postnatal day (PD21) to the completion of restraint stress on the 97th postnatal day (PD97), the mice were fed with Erxian decoction mixed with diet. The anxiety state of mice was evaluated by open field test and elevated O-maze test. The content of plasma corticosterone (CORT) in mice was detected by enzyme-linked immunosorbent assay (ELISA). The expression levels of protein kinase B (Akt1), mammalian target of rapamycin (mTOR), brain-derived neurotrophic factor (BDNF), postsynaptic density-95 (PSD95), and synaptophysin in the hippocampus of mice were detected by Western blot and real-time quantitative polymerase chain reaction (Real-time PCR). ResultNinty-seven active components and 227 action targets of Erxian decoction were obtained. There were 3 863 targets related to anxiety disorder, with 161 drug-disease intersection targets. Among these intersection targets, core targets such as Akt1, interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor (TNF), and mTOR were presumedly closely related to anxiety disorder. The results of KEGG pathway analysis showed that Erxian decoction mainly treated anxiety disorder through phosphatidylinositol 3-kinase (PI3K)/Akt, mitogen-activated protein kinase (MAPK), and neuroactive ligand-receptor interaction signaling pathways. The results of animal experiments showed that compared with the model group, the Erxian decoction group significantly increased the time of mice spent in the central zone and central crossing times and time spent in the opened arm and opened arm crossing times, with significantly increased expression levels of p-Akt1, p-mTOR, BDNF, PSD95, and synaptophysin (Syp). ConclusionErxian decoction has the multi-target and multi-pathway characteristics in the treatment of anxiety disorder, and its mechanism may be related to the improvement of synaptic plasticity and neuroinflammation by affecting Akt1, IL-1β, IL-6, TNF, mTOR, and other core targets and modulating PI3K/Akt, MAPK, as well as neuroactive ligand-receptor interaction signal pathways.
RESUMEN
ObjectiveTo preliminarily predict the active components, targets, and signaling pathways of modified Shengjiangsan in the treatment of immunoglobulin A nephropathy (IgAN) based on network pharmacology, and to explore its underlying mechanism through molecular docking and experimental verification on animals. MethodThe active ingredients and related targets of modified Shengjiangsan were obtained from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP), UniProt, SwissTargetPrediction, and literature review. IgAN-related targets were obtained from GeneCards and Online Mendelian Inheritance in Man (OMIM). Cytoscape 3.9.0 was used to construct the regulation network of the related targets of Shengjiangsan and IgAN, and the protein-protein interaction (PPI) network was plotted by STRING. The common genes were analyzed for gene ontology (GO) functional annotation and Kyoto encyclopedia of genes and genomes(KEGG) pathway enrichment by Metascape. Key targets and main active ingredients were selected for molecular docking by AutoDockTools 1.5.6. The experimental model of IgAN was induced by bovine serum albumin(BSA, ig) combined with lipopolysaccharide (LPS, iv) and the complex of CCl4 and castor oil (sc) in rats. The model rats were treated with modified Shengjiangsan and benazepril hydrochloride for four weeks. The rats were sacrificed after drug administration. The levels of transforming growth factor-β1 (TGF-β1) and interleukin-6 (IL-6) in the serum and kidney tissues were detected by enzyme-linked immunosorbent assay(ELISA), immunohistochemistry, Real-time quantitative polymerase chain reaction (Real-time PCR), and Western blot. ResultA total of 105 active ingredients were obtained according to oral bioavailability(OB), drug-likeness(DL), and literature screening. There were 124 common genes and 59 core targets. Neurotrophic tyrosine receptor kinase 1 (NTRK1), cullin-3 (CUL3), tumor protein 53 (TP53), epidermal growth factor receptor (EGFR), exportin 1 (XPO1), and other targets might be closely related to IgAN. As predicted by KEGG enrichment analysis, the treatment of IgAN with modified Shengjiangsan mainly involved the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway, nuclear transcription factor-kappa B (NF-κB) signaling pathway, and cytokine-cytokine receptor interaction signaling pathway. As revealed by molecular docking, the main active ingredients in modified Shengjiangsan showed stable binding activities with NTRK1, CUL3, TP53, EGFR, and XPO1 in the core targets, indicating that it presumedly regulated inflammatory responses by affecting NTRK1, CUL3, TP53, EGFR, and XPO1 target proteins. The results of experimental verification on animals showed that the expression levels of cytokines TGF-β1 and IL-6 in the serum and kidney tissues of IgAN rats were significantly decreased by modified Shengjiangsan, suggesting that Shengjiangsan might inhibit excessive fibrosis, and inflammatory and immune responses by regulating signaling pathways such as cytokine-cytokine receptor interaction, PI3K/Akt, and NF-κB. ConclusionModified Shengjiangsan may treat IgAN through multiple targets and pathways. Its mechanism may be related to the inhibition of excessive fibrosis, and inflammatory and immune responses by affecting the expression of NTRK1, CUL3, TP53, EGFR, and XPO1 and the regulation of the cytokine-cytokine receptor interaction, PI3K/Akt, NF-κB, and other signaling pathways.
RESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: The antitumor effects of Grifola frondosa/maitake polysaccharide (GFP) have been reported in many preclinical studies, especially in vivo experiments. The present meta-analysis aimed to provide an in vivo evidence and theoretical basis for future clinical trials by assessing the efficacy and underlying mechanisms of GFP in tumor treatment. MATERIALS AND METHODS: English and Chinese databases were examined to include animal experiments to study the antitumor activity of GFP. Literature screening, data extraction, and meta-analysis were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. In addition, the Systematic Review Center for Laboratory animal Experimentation (SYRCLE) risk of bias (RoB) tool was used to assess the risk of bias of the included animal studies. RESULTS: Potentially relevant studies (442) were identified, and finally 24 eligible studies (all in English) were included. The meta-analysis revealed that GFP has significant effects in inhibiting tumor growth (high dose: mean difference (MD) = -1.34, 95% confidence interval (CI) = [-1.73, -0.95]; low dose: MD = -5.68, 95% CI = [-7.27, -4.09]), improving tumor remission rate (odds ratio = 25.59, 95% CI = [9.08, 72.11]), and enhancing immune function in both cellular (CD4+ T cell percentage: MD = 3.03, 95% CI = [1.16, 4.90]; CD8+ T cell percentage: MD = 1.10, 95% CI = [-0.29, 2.49]) and humoral immunity (MD and [95% CI] of interleukin (IL)-2, IL-12 and tumor necrosis factor-α were 7.86 [6.29, 9.44], 35.95 [5.18, 66.72], and 10.03 [8.71, 11.36], respectively), and the differences between the two groups of the above indicators were statistically significant (all P < 0.01) except CD8+ T cell percentage. Additionally, the quality of the included studies was not high, and the risk of bias mainly concentrated on selection, detection, and reporting biases. CONCLUSION: GFP is a potential candidate for tumor treatment and clinical trials. TRIAL REGISTRATION: The review protocol for this study was registered with the PROSPERO database before beginning the review process (CRD42018108897).
Asunto(s)
Antineoplásicos/farmacología , Grifola/química , Polisacáridos/farmacología , Animales , Antineoplásicos/administración & dosificación , Relación Dosis-Respuesta a Droga , Humanos , Neoplasias/tratamiento farmacológico , Polisacáridos/administración & dosificación , Polisacáridos/aislamiento & purificaciónRESUMEN
Objective:To review and summarize the current research status of traditional Chinese medicine(TCM) for the treatment of chronic atrophic gastritis(CAG),provide references and hints for relevant studies,and contribute to the further understanding of TCM and the application of TCM in the treatment of CAG with scientific evidence. Method:The PubMed and Web of Science databases were searched for relevant literature on the treatment of CAG with TCM from their establishment to August 31,2020. Eligible randomized controlled trials (RCTs) and animal studies were included according to the inclusion and exclusion criteria,and then the information of the included studies was extracted,summarized,and organized for further analysis. Result:A total of 4 RCTs and 21 animal studies (including 13 papers on compound studies,3 papers on single herb studies,and 5 papers on monomer studies) about TCM treatment for CAG were included in this study. RCTs showed that TCM could work well in improving the pathological state of gastric mucosa and clinical symptoms in patients. However,there were problems of low study quality,and non-uniform diagnostic criteria for gastric mucosal pathology and clinical efficiency evaluation. Animal experiments mainly focused on the study of drug mechanism exploration,and their results showed that TCM treatment of CAG was characterized by multi-target action. However,the animal experiments also had some problems such as inconsistence of CAG animal model establishment,positive drug selection,drug intervention methods as well as intervention cycles among different experiments. Conclusion:The efficacy of TCM in the treatment of CAG has gradually gained global recognition,but there is still a need for further standardization and unification of research methods. In the future,high-quality clinical trials and standardized animal experiments are still needed to conduct in-depth studies on the time for intervention,intervention methods,active ingredients and mechanisms of TCM,so as to make contributions to the full understanding and application of TCM in the treatment of CAG.
RESUMEN
Sodium bicarbonate, commonly known as baking soda, is widely used in the clinic as an antacid for treating gastric hyperacidity, among other conditions. Chao et al have reported a clinical trial about targeting intratumor lactic acidosis-transarterial chemoembolization. Based on conventional transarterial chemoembolization, the authors added a 5% sodium bicarbonate solution to cytotoxic drugs, resulting in a high local control rate. The explanation for the antitumor effects of sodium bicarbonate is related to acidosis in the tumor microenvironment. In this review, we summarize the findings from studies administering sodium bicarbonate alone or in combination with other anticancer therapies as cancer treatments, and discuss methods for safe and effective use of sodium bicarbonate in the clinic.
Asunto(s)
Carcinoma Hepatocelular , Quimioembolización Terapéutica , Neoplasias , Bicarbonato de Sodio , Humanos , Concentración de Iones de Hidrógeno , Neoplasias/terapia , Bicarbonato de Sodio/uso terapéutico , Microambiente TumoralRESUMEN
ETHNOPHARMACOLOGICAL RELEVANCE: Shuxuening injection (SXNI), a popular herbal medicine, is an extract of Ginkgo biloba leaves (GBE), and is used to treat ischemic stroke (IS) in China. However, its specific active ingredients and molecular mechanisms in IS remain unclear. AIM OF THE STUDY: The purpose of the research is to identify the main active ingredients in GBE and explore its molecular mechanisms in the treatment of IS. MATERIALS AND METHODS: The main active components of GBE were discerned through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis (TCMSP), Traditional Chinese Medicine Integrated Database (TCMID), Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM) database, and absorption, distribution, metabolism and excretion (ADME) analysis. The targets related to IS were obtained using Genecards, Online Mendelian Inheritance in Man (OMIM), Therapeutic Target Database (TTD), and Disgenet. We discovered an intersection of genes. Subsequently, protein-protein interaction (PPI) networks were constructed with Cytoscape 3.7.1 and the String database. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to analyze the intersection of targets via the Database for Annotation, Visualization, and Integrated Discovery (DAVID) 6.8. Built on the above analysis, we made a Compound-Target-Pathway (C-T-P) network. Autodock Vina was used for molecular docking analysis. Maestro 11.9 was used to calculate the root-mean-square deviation (RMSD). Animal experiments were performed to verify the core targets. Triphenyl tetrazolium chloride (TTC) staining was used to calculate the infarct volume in rats. Hematoxylin-eosin (HE) staining was employed to observe the morphology of hippocampal neuron cells. RT-qPCR was applied to detect relative mRNA levels, and protein expression was determined using Western blotting. RESULTS: Molecular docking showed that PTGS2, NOS3 and CASP3 docked with small molecule compounds. According to RT-qPCR and Western blotting, mRNA and protein expression of PTGS2 and CASP3 were up-regulated (P < 0.05), and mRNA and protein levels of NOS3 were down-regulated (P < 0.05). CONCLUSIONS: SXNI can treat IS through multiple targets and routes, and reduce the apoptosis of neuron cells in brain tissue by inhibiting inflammation and regulating the level of oxidative stress, thereby protecting rats brain tissue.
Asunto(s)
Encéfalo/efectos de los fármacos , Medicamentos Herbarios Chinos/administración & dosificación , Infarto de la Arteria Cerebral Media/tratamiento farmacológico , Accidente Cerebrovascular Isquémico/tratamiento farmacológico , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/administración & dosificación , Biología de Sistemas , Animales , Antiinflamatorios/administración & dosificación , Antioxidantes/administración & dosificación , Apoptosis/efectos de los fármacos , Proteínas Reguladoras de la Apoptosis/genética , Proteínas Reguladoras de la Apoptosis/metabolismo , Encéfalo/metabolismo , Encéfalo/patología , Bases de Datos Genéticas , Modelos Animales de Enfermedad , Regulación de la Expresión Génica , Redes Reguladoras de Genes , Estudios de Asociación Genética , Infarto de la Arteria Cerebral Media/genética , Infarto de la Arteria Cerebral Media/metabolismo , Infarto de la Arteria Cerebral Media/patología , Mediadores de Inflamación/metabolismo , Inyecciones Intravenosas , Accidente Cerebrovascular Isquémico/genética , Accidente Cerebrovascular Isquémico/metabolismo , Accidente Cerebrovascular Isquémico/patología , Simulación del Acoplamiento Molecular , Neuronas/metabolismo , Neuronas/patología , Estrés Oxidativo/efectos de los fármacos , Mapas de Interacción de Proteínas , Ratas Sprague-Dawley , Transducción de SeñalRESUMEN
OBJECTIVE: To systematically review the effectiveness and safety of electroacupuncture (EA) on hyperlipidemia combined with atherosclerosis in animal experiments. METHODS: The relevant animal experiments of EA treatment for hyperlipidemia combined with atherosclerosis were retrieved from the CNKI, WANFANG, VIP, CBM, PubMed, Embase and the Cochrane Library up to March 19, 2018 since the establishment of databases. Two researchers in the project team screened the literature and extracted the information such as experiment objects, experiment steps and experiment results separately. The literature assessment was evaluated. Meta analysis was performed with RevMan 5.3 software. RESULTS: Eventually, 29 eligible experimental researches were included and the average score in the quality assessment was 5.1, at the moderate level. Meta analysis showed that compared with the model control group, after EA treatment, the levels of the total cholesterol (TC) [SMD -2.29, 95% CI (-2.94, -1.64), P<0.000 01], triglyceride (TG) [SMD -1.30, 95% CI (-1.76, -0.84), P<0.000 01] and low density lipoprotein-cholesterol (LDL-C) [SMD -2.64, 95% CI (-3.29, -1.99), P<0.000 01] were significantly reduced and the level of high density lipoprotein-cholesterol (HDL-C) [SMD 0.55, 95% CI (0.06, 1.04), P =0.03] was increased, indicating the significant differences. CONCLUSION: On the base of the current limited evidences, EA significantly reduces the levels of TC, TG and LDL-C and slightly increases the level of HDL-C in the animal models of hyperlipidemia combined with atherosclerosis.
Asunto(s)
Aterosclerosis , Electroacupuntura , Hiperlipidemias , Experimentación Animal , Animales , Aterosclerosis/terapia , LDL-Colesterol , HumanosRESUMEN
BACKGROUND: Osteonecrosis of the femoral head (ONFH) is a common joint disease and a major cause of morbidity. OBJECTIVE: In this study Cervi cornus Colla (CCC) deproteinized bone scaffolds were designed and three dimensional (3D)-printed for the repair of ONFH in rats. MATERIAL AND METHODS: The CCC-deproteinized bone scaffolds were 3D-printed using polycaprolactone mixed with the CCC-deproteinized bone powder. The scaffolds were viewed under a scanning electron microscope and subjected to compression analysis. Osteoblasts were isolated from rats and coated onto the scaffolds. Cell proliferation assays were performed with the MTT (3[4,5-dimethylthiazole2]-2,5-diphenyltetrazolium bromide) kit from Promega. An ONFH was induced in rats and a CCC-deproteinized bone scaffold was implanted into the necrotic femoral head. General observations, Xray imaging, and pathological examination of the femoral head were performed to evaluate the treatment of ONFH in the rats. RESULTS: The scaffolds were porous with a mean pore diameter of 315.70⯱ 41.52â¯nm and a porosity of 72.86⯱ 5.45% and exhibited favorable mechanical properties and degradation. In vitro assays showed that osteoblasts accumulated in the pores and adhered to the scaffolds. The CCC-deproteinized bone scaffolds enhanced the proliferation of osteoblasts. The in vivo experiments revealed that the general observation score of rats in the CCC-scaffold implanted group was significantly higher than that in the control group. The Xray images showed significant alleviation of ONFH in the CCC-deproteinized bone scaffold implanted rats. The femoral heads of rats in the treatment group showed less destruction or ossification of cartilage cells, few bone cement lines, very little necrosis or irregularities on the cartilage surface and only a small amount of inflammatory cell infiltration in the medullary cavity. CONCLUSION: These results suggest that CCC-deproteinized bone scaffold implants facilitated the repair of ONFH in rats. This research provides a new therapeutic approach for the repair of early and mid-term ONFH.
Asunto(s)
Fémur , Osteonecrosis/terapia , Impresión Tridimensional , Andamios del Tejido , Animales , RatasRESUMEN
OBJECTIVE@#To systematically review the effectiveness and safety of electroacupuncture (EA) on hyperlipidemia combined with atherosclerosis in animal experiments.@*METHODS@#The relevant animal experiments of EA treatment for hyperlipidemia combined with atherosclerosis were retrieved from the CNKI, WANFANG, VIP, CBM, PubMed, Embase and the Cochrane Library up to March 19, 2018 since the establishment of databases. Two researchers in the project team screened the literature and extracted the information such as experiment objects, experiment steps and experiment results separately. The literature assessment was evaluated. Meta analysis was performed with RevMan 5.3 software.@*RESULTS@#Eventually, 29 eligible experimental researches were included and the average score in the quality assessment was 5.1, at the moderate level. Meta analysis showed that compared with the model control group, after EA treatment, the levels of the total cholesterol (TC) [ -2.29, 95% (-2.94, -1.64), <0.000 01], triglyceride (TG) [ -1.30, 95% (-1.76, -0.84), <0.000 01] and low density lipoprotein-cholesterol (LDL-C) [ -2.64, 95% (-3.29, -1.99), <0.000 01] were significantly reduced and the level of high density lipoprotein-cholesterol (HDL-C) [ 0.55, 95% (0.06, 1.04), =0.03] was increased, indicating the significant differences.@*CONCLUSION@#On the base of the current limited evidences, EA significantly reduces the levels of TC, TG and LDL-C and slightly increases the level of HDL-C in the animal models of hyperlipidemia combined with atherosclerosis.
Asunto(s)
Animales , Humanos , Experimentación Animal , Aterosclerosis , Terapéutica , LDL-Colesterol , Electroacupuntura , HiperlipidemiasRESUMEN
Objective To evaluate the change of serum creatinine (Scr) before and after administration of contrast agent in different dose,to observe the difference of dog's kidney tissue with electron microscopy and investigate the effect of contrast agent on renal function.Methods Twelve dogs were divided into four groups randomly:the control group,the low dose group,the moderate dose group and high dose group.After the administration of different doses of iodine contrast agent at the same rate,the changes of Scr and microscopic structure were compared before administration and 48 hours later.Results The differences of Scr before and 48 hours after administration were (4.6±1.6) μmol/L,(6.7±2.5) μmol/L,(6.9±4.5) μmol/L,(5.1± 1.9) μmol/L for control group,low dose group,moderate dose group and high dose group,respectively.There was no statistically significant difference among the groups (P >0.05).In high dose group,the mitochondria of tubular epithelial cells were swelling and obvious vacuoles were observed.Only a small amount of vacuoles existed in the renal tubular epithelial cells in low dose group.Conclusion Compared with the moderate and high dose group,the low-dose iodine contrast agent have less damage to the kidney cells of the dogs.